2015
DOI: 10.1016/j.ejca.2015.07.010
|View full text |Cite
|
Sign up to set email alerts
|

The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours

Abstract: In this real-world GIST registry, patients with advanced GIST were treated with imatinib and patients with localised GIST received surgical resection, in accordance with prevailing clinical recommendations.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
26
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 33 publications
(27 citation statements)
references
References 31 publications
1
26
0
Order By: Relevance
“…Because of the presence of KIT or PDGFRA mutations in the majority of patients with GIST, imatinib mesylate, a selective tyrosine kinase inhibitor (TKI), has been written into consensus at home and abroad as the first-line treatment for patients with GIST (7)(8)(9). Consummate pathologic examination and genetic testing can predict the efficacy of imatinib mesylate for patients with GIST, especially with the KIT and PDGFRA mutations (10)(11)(12)(13). The response rate to imatinib in patients with GIST with KIT exon 9 mutations is 48%, approximately as half as that of patients with exon 11 mutations (83.5%).…”
Section: Introductionmentioning
confidence: 99%
“…Because of the presence of KIT or PDGFRA mutations in the majority of patients with GIST, imatinib mesylate, a selective tyrosine kinase inhibitor (TKI), has been written into consensus at home and abroad as the first-line treatment for patients with GIST (7)(8)(9). Consummate pathologic examination and genetic testing can predict the efficacy of imatinib mesylate for patients with GIST, especially with the KIT and PDGFRA mutations (10)(11)(12)(13). The response rate to imatinib in patients with GIST with KIT exon 9 mutations is 48%, approximately as half as that of patients with exon 11 mutations (83.5%).…”
Section: Introductionmentioning
confidence: 99%
“…These rare malignancies represent around 5% of all the gastric neoplasms, and most commonly include GISTs, NENs of the stomach, and/or primary gastric lymphomas. [3][4][5] From the molecular standpoint, the pathogenesis of gastric tumors is diverse, and even though several risk factors for stomach cancer have been identified recently, the exact biochemical and cellular mechanisms underlying the formation of gastric tumors remain only partially known.…”
Section: Introductionmentioning
confidence: 99%
“…Other less frequently occurring types of neoplasms, which may have milder and less debilitating clinical outcomes, may also develop within the gastric tissue. These include gastrointestinal stromal tumors (GISTs), neuroendocrine neoplasms (NENs), and/or diverse types of gastric lymphomas456789. However, even though significant effort has been directed toward elucidating the pathogenesis of various types of gastric neoplasms, the exact mechanisms and factors responsible for the development and/or progression of these tumors in humans remain unknown.…”
mentioning
confidence: 99%